Bayer Shares Crash Most on Record After Monsanto Cancer Trial Loss

Note to readers: please click the share buttons above  

Bayer AG shares are down over 12% this morning – the biggest drop ever – to the lowest levels since October 2013, amid investor anxiety over the potential future legal costs associated with newly-acquired Monsanto’s RoundUp weedkiller.

As we detailed Friday,  a San Francisco Jury awarded $289 million in damages to a former school groundskeeper, Dewayne Johnson, who said Monsanto’s Roundup weedkiller gave him terminal cancer.

The trial was an important test of the evidence against Monsanto and will serve as a template for litigating thousands of other claims over the herbicide.

As Bloomberg reports, the verdict surprised Bayer investors and may stir up memories of the scandal over cholesterol-lowering pill Lipobay, said Markus Mayer, an analyst with Baader Bank AG. Bayer paid more than $1.1 billion to settle suits over the heart drug.

“Investors might worry that this will become a ‘Lipobay 2.0,’” Mayer said.

The company, whose market value fell by more than 10 billion euros ($11.4 billion) Monday, says Roundup is safe.

“They’re going to appeal, and we’re going to have to see what happens then,” said Ulrich Huwald, an analyst with Warburg Research in Hamburg. Even if Bayer doesn’t face similar verdicts in other cases, the company may need to pay out settlements. “As the northern Germans say, ‘In court and on the high seas, you’re in God’s hands.’”

Bayer closed a deal to buy Monsanto for $66 billion in June. If the litigation generates large verdicts, it could have a material impact on Bayer’s bottom line, said Chris Perrella, an analyst for Bloomberg Intelligence.


Articles by: Zero Hedge

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]